Immunoproteasome in animal models of Duchenne muscular dystrophy

Chiao Nan Joyce Chen, Ted G. Graber, Wendy M. Bratten, Deborah A. Ferrington, Ladora V. Thompson

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Increased proteasome activity has been implicated in the atrophy and deterioration associated with dystrophic muscles of Duchenne muscular dystrophy (DMD). While proteasome inhibitors show promise in the attenuation of muscle degeneration, proteasome inhibition-induced toxicity was a major drawback of this therapeutic strategy. Inhibitors that selectively target the proteasome subtype that is responsible for the loss in muscle mass and quality would reduce side effects and be less toxic. This study examined proteasome activity and subtype populations, along with muscle function, morphology and damage in wild-type (WT) mice and two murine models of DMD, dystrophin-deficient (MDX) and dystrophin- and utrophin-double-knockout (DKO) mice. We found that immunoproteasome content was increased in dystrophic muscles while the total proteasome content was unchanged among the three genotypes of mice. Proteasome proteolytic activity was elevated in dystrophic muscles, especially in DKO mice. These mice also exhibited more severe muscle atrophy than either WT or MDX mice. Muscle damage and regeneration, characterized by the activity of muscle creatine kinase in the blood and the percentage of central nuclei were equally increased in dystrophic mice. Accordingly, the overall muscle function was similarly reduced in both dystrophic mice compared with WT. These data demonstrated that there was transformation of standard proteasomes to immunoproteasomes in dystrophic muscles. In addition, DKO that showed greatest increase in proteasome activities also demonstrated more severe atrophy compared with MDX and WT. These results suggest a putative role for the immunoproteasome in muscle deterioration associated with DMD and provide a potential target for therapeutic intervention.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalJournal of muscle research and cell motility
Volume35
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Duchenne Muscular Dystrophy
Muscle
Proteasome Endopeptidase Complex
Animals
Animal Models
Muscles
Dystrophin
Knockout Mice
Atrophy
Deterioration
Utrophin
MM Form Creatine Kinase
Proteasome Inhibitors
Muscular Atrophy
Poisons
Regeneration
Toxicity
Genotype
Blood

Keywords

  • Duchenne muscular dystrophy
  • Immunoproteasome
  • LC3
  • LMP2
  • LMP7
  • Proteasome

Cite this

Immunoproteasome in animal models of Duchenne muscular dystrophy. / Chen, Chiao Nan Joyce; Graber, Ted G.; Bratten, Wendy M.; Ferrington, Deborah A.; Thompson, Ladora V.

In: Journal of muscle research and cell motility, Vol. 35, No. 2, 01.01.2014, p. 191-201.

Research output: Contribution to journalArticle

Chen, Chiao Nan Joyce ; Graber, Ted G. ; Bratten, Wendy M. ; Ferrington, Deborah A. ; Thompson, Ladora V. / Immunoproteasome in animal models of Duchenne muscular dystrophy. In: Journal of muscle research and cell motility. 2014 ; Vol. 35, No. 2. pp. 191-201.
@article{375848a1c6b2481ca4c1b29ef9aeeac1,
title = "Immunoproteasome in animal models of Duchenne muscular dystrophy",
abstract = "Increased proteasome activity has been implicated in the atrophy and deterioration associated with dystrophic muscles of Duchenne muscular dystrophy (DMD). While proteasome inhibitors show promise in the attenuation of muscle degeneration, proteasome inhibition-induced toxicity was a major drawback of this therapeutic strategy. Inhibitors that selectively target the proteasome subtype that is responsible for the loss in muscle mass and quality would reduce side effects and be less toxic. This study examined proteasome activity and subtype populations, along with muscle function, morphology and damage in wild-type (WT) mice and two murine models of DMD, dystrophin-deficient (MDX) and dystrophin- and utrophin-double-knockout (DKO) mice. We found that immunoproteasome content was increased in dystrophic muscles while the total proteasome content was unchanged among the three genotypes of mice. Proteasome proteolytic activity was elevated in dystrophic muscles, especially in DKO mice. These mice also exhibited more severe muscle atrophy than either WT or MDX mice. Muscle damage and regeneration, characterized by the activity of muscle creatine kinase in the blood and the percentage of central nuclei were equally increased in dystrophic mice. Accordingly, the overall muscle function was similarly reduced in both dystrophic mice compared with WT. These data demonstrated that there was transformation of standard proteasomes to immunoproteasomes in dystrophic muscles. In addition, DKO that showed greatest increase in proteasome activities also demonstrated more severe atrophy compared with MDX and WT. These results suggest a putative role for the immunoproteasome in muscle deterioration associated with DMD and provide a potential target for therapeutic intervention.",
keywords = "Duchenne muscular dystrophy, Immunoproteasome, LC3, LMP2, LMP7, Proteasome",
author = "Chen, {Chiao Nan Joyce} and Graber, {Ted G.} and Bratten, {Wendy M.} and Ferrington, {Deborah A.} and Thompson, {Ladora V.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10974-014-9385-x",
language = "English (US)",
volume = "35",
pages = "191--201",
journal = "Journal of Muscle Research and Cell Motility",
issn = "0142-4319",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Immunoproteasome in animal models of Duchenne muscular dystrophy

AU - Chen, Chiao Nan Joyce

AU - Graber, Ted G.

AU - Bratten, Wendy M.

AU - Ferrington, Deborah A.

AU - Thompson, Ladora V.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Increased proteasome activity has been implicated in the atrophy and deterioration associated with dystrophic muscles of Duchenne muscular dystrophy (DMD). While proteasome inhibitors show promise in the attenuation of muscle degeneration, proteasome inhibition-induced toxicity was a major drawback of this therapeutic strategy. Inhibitors that selectively target the proteasome subtype that is responsible for the loss in muscle mass and quality would reduce side effects and be less toxic. This study examined proteasome activity and subtype populations, along with muscle function, morphology and damage in wild-type (WT) mice and two murine models of DMD, dystrophin-deficient (MDX) and dystrophin- and utrophin-double-knockout (DKO) mice. We found that immunoproteasome content was increased in dystrophic muscles while the total proteasome content was unchanged among the three genotypes of mice. Proteasome proteolytic activity was elevated in dystrophic muscles, especially in DKO mice. These mice also exhibited more severe muscle atrophy than either WT or MDX mice. Muscle damage and regeneration, characterized by the activity of muscle creatine kinase in the blood and the percentage of central nuclei were equally increased in dystrophic mice. Accordingly, the overall muscle function was similarly reduced in both dystrophic mice compared with WT. These data demonstrated that there was transformation of standard proteasomes to immunoproteasomes in dystrophic muscles. In addition, DKO that showed greatest increase in proteasome activities also demonstrated more severe atrophy compared with MDX and WT. These results suggest a putative role for the immunoproteasome in muscle deterioration associated with DMD and provide a potential target for therapeutic intervention.

AB - Increased proteasome activity has been implicated in the atrophy and deterioration associated with dystrophic muscles of Duchenne muscular dystrophy (DMD). While proteasome inhibitors show promise in the attenuation of muscle degeneration, proteasome inhibition-induced toxicity was a major drawback of this therapeutic strategy. Inhibitors that selectively target the proteasome subtype that is responsible for the loss in muscle mass and quality would reduce side effects and be less toxic. This study examined proteasome activity and subtype populations, along with muscle function, morphology and damage in wild-type (WT) mice and two murine models of DMD, dystrophin-deficient (MDX) and dystrophin- and utrophin-double-knockout (DKO) mice. We found that immunoproteasome content was increased in dystrophic muscles while the total proteasome content was unchanged among the three genotypes of mice. Proteasome proteolytic activity was elevated in dystrophic muscles, especially in DKO mice. These mice also exhibited more severe muscle atrophy than either WT or MDX mice. Muscle damage and regeneration, characterized by the activity of muscle creatine kinase in the blood and the percentage of central nuclei were equally increased in dystrophic mice. Accordingly, the overall muscle function was similarly reduced in both dystrophic mice compared with WT. These data demonstrated that there was transformation of standard proteasomes to immunoproteasomes in dystrophic muscles. In addition, DKO that showed greatest increase in proteasome activities also demonstrated more severe atrophy compared with MDX and WT. These results suggest a putative role for the immunoproteasome in muscle deterioration associated with DMD and provide a potential target for therapeutic intervention.

KW - Duchenne muscular dystrophy

KW - Immunoproteasome

KW - LC3

KW - LMP2

KW - LMP7

KW - Proteasome

UR - http://www.scopus.com/inward/record.url?scp=84904270015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904270015&partnerID=8YFLogxK

U2 - 10.1007/s10974-014-9385-x

DO - 10.1007/s10974-014-9385-x

M3 - Article

C2 - 24934129

AN - SCOPUS:84904270015

VL - 35

SP - 191

EP - 201

JO - Journal of Muscle Research and Cell Motility

JF - Journal of Muscle Research and Cell Motility

SN - 0142-4319

IS - 2

ER -